基于人血清白蛋白的纳米粒子用于向的细胞内药物输送
Claudia Gabriela Chilom1, Sorina Iftimie1, Adriana Elena Balan1
1Faculty of Physics, University of Bucharest Magurele, 077125 Magurele, Ilfov, Romania.
International journal of molecular sciences
|September 13, 2025
概括
叶酸结合的阿尔伯明纳米颗粒有效地将抗癌类黄素 rutin 传递给结肠癌细胞. 这种有针对性的方法提高了对癌细胞的疗效,同时保留了健康细胞,显示了结直肠癌治疗的前景.
科学领域:
- 生物材料科学 生物材料科学
- 纳米技术纳米技术
- 癌症治疗方法 癌症治疗方法
背景情况:
- 像鲁丁这样的黄类化合物具有抗癌性质,但需要有效的输送系统.
- 有针对性的药物输送旨在提高治疗效率并减少副作用.
- 叶酸受体过度表达在各种癌细胞中很常见,为选择性输送提供了目标.
研究的目的:
- 为了合成和表征与叶酸结合的人体血清蛋白纳米颗粒 (HSA-FA) 装载着素 (Ru).
- 评估这些纳米颗粒对结肠癌细胞的向输送和抗癌疗效.
- 评估纳米载体系统的生物相容性和细胞吸收.
主要方法:
- 纳米粒子使用溶解法制备,并用叶酸功能化.
- 描述涉及原子力显微镜 (AFM),扫描电子显微镜 (SEM) 和光显微镜.
- 使用HT-29结肠癌细胞和L929纤维细胞的MTS测定来评估生物活性.
主要成果:
- 合成的 (HSA-FA):Ru纳米粒子尺寸均 (<100 nm) 和稳定.
- 电压测量证实了素和叶酸的成功装载.
- 这些纳米颗粒对HT-29细胞具有显著的细胞毒性,对L929细胞的影响最小.
- 在HT-29细胞中观察到偏好的吸收和积累,证实了向的输送.
结论:
- 用叶酸功能化的基于HSA的纳米颗粒作为 rutin 的高效和生物相容的载体.
- 这种有针对性的纳米递送系统显示了在结直肠癌治疗中选择性细胞内药物递送的潜力.
- 这些发现支持开发基于白蛋白的纳米载体,用于先进的癌症治疗.
相关概念视频
Modified-Release Drug Delivery Systems: Site-Targeted
Site-targeted drug delivery systems enhance therapeutic efficacy while minimizing systemic toxicity and treatment costs. Unlike conventional methods, these systems ensure precise drug delivery, improving bioavailability and reducing side effects. Targeted drug delivery is classified into three levels. First-order targeting directs drugs to the capillary beds of specific organs or tissues. Second-order targets specific cell types, such as tumor cells, using receptor-mediated interactions.
Site-Targeted Drug Delivery Systems: Polymeric Carriers
Polymeric carriers enhance targeted drug delivery by increasing efficacy while minimizing off-target effects. These carriers comprise a biodegradable polymeric backbone integrated with functional elements that enable targeting, improve physicochemical properties, and regulate drug release.Targeting MechanismsThe targeting ability of polymeric carriers is mediated by a homing device, which is a molecular recognition component designed to selectively bind to specific tissues or cells. Monoclonal...


